Myriad Genetics, Tesaro deal

Tesaro will use Myriad's Homologous Recombination Deficiency (HRD) test to identify tumor types that may respond to Tesaro's niraparib. The oral poly(ADP-ribose) polymerase (PARP) inhibitor is in Phase III testing to treat breast and ovarian cancer. Myriad's HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs. The partners declined to disclose details. Tesaro has exclusive, worldwide rights to niraparib from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) (see BioCentury, June 11, 2012). ...